FDA approved vs. Pharmacy compounded 17-OHPC—current issues for obstetricians to consider in reducing recurrent preterm birth

References

• Thom EA, Rice MM, Saade GR, et al. What we have learned about the design of randomized trials in pregnancy. Semin Perinatol. 2016;40(5):328–334.
   PubMed Web of Science ®Google Scholar
• March of Dimes. 2019. March of Dimes Report Card; [cited 2020 May 21]. Available from: https://www.marchofdimes.org/mission/reportcard.aspx.
   Google Scholar
• Mercer BM, Goldenberg RL, Moawad AH, et al. The preterm prediction study: effect of gestational age and cause of preterm birth on subsequent obstetric outcome. Am J Obstet Gynecol. 1999;181(5):1216–1221.
   PubMed Web of Science ®Google Scholar
• Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003;348(24):2379–2385.
   PubMed Web of Science ®Google Scholar
• Iams JD, Newman RB, Thom EA, et al. Frequency of uterine contractions and the risk of spontaneous preterm delivery. N Engl J Med. 2002;346(4):250–255.
   PubMed Web of Science ®Google Scholar
• Iams JD. Was the preterm birth rate in the placebo group too high in the Meis MFMU Network trial of 17-OHPC? Am J Obstet Gynecol. 2010;202(5):409–410.
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. ACOG committee opinion. Use of progesterone to reduce preterm birth. Number 291, November 2003. Int J Gynecol Obstet. 2004;84:93–94.
   PubMed Web of Science ®Google Scholar
• Da Fonseca EB, Bittar RE, Carvalho MH, et al. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol. 2003;188(2):419–424.
   PubMed Web of Science ®Google Scholar
• Ness A, Dias T, Damus K, et al. Impact of the recent randomized trials on the use of progesterone to prevent preterm birth: a 2005 follow-up survey. Am J Obstet Gynecol. 2006;195(4):1174–1179.
   PubMed Web of Science ®Google Scholar
• Henderson ZT, Power ML, Berghella V, et al. Attitudes and practices regarding use of progesterone to prevent preterm births. Am J Perinatol. 2009;26(7):529–536.
   PubMed Web of Science ®Google Scholar
• Keirse MJ. Progestogen administration in pregnancy may prevent preterm delivery. Br J Obstet Gynaecol. 1990;97(2):149–154.
   PubMedGoogle Scholar
• Division of Bone, Reproductive, and Urologic Products. Office of New Drugs, Center for Drug Evaluation and Research. Food and Drug Administration. Bone, Reproductive, and Urologic Drugs Advisory Committee (BRUDAC) Meeting October 29, 2019. FDA Briefing Document NDA 021945. Hydroxyprogesterone Caproate Injection (trade name Makena). October 2019; [cited 2020 Mar 27]. Available from: https://www.fda.gov/media/132003/download.
   Google Scholar
• Division of Bone, Reproductive, and Urologic Products. Center for Drug Evaluation and Research. Medical Review: Application number 21945Orig1s000. February 2011; [cited 2020 Mar 29]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021945Orig1s000MedR.pdf.
   Google Scholar
• Sellers S, Utian WH. Pharmacy compounding primer for physicians. Prescriber beware. Drugs. 2012;72(16):2043– 2050.
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. FDA statement on Makena. March 30, 2011; [cited 2020 Mar 29]. Available from: https://wayback.archive-it.org/7993/20170113192840/. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm249025.htm.
   Google Scholar
• Chollet JL, Jozwiakowski MJ. Quality investigation of hydroxyprogesterone caproate active pharmaceutical ingredient and injection. Drug Dev Ind Pharm. 2012;38(5):540–549.
   PubMed Web of Science ®Google Scholar
• Meis PJ. The source of 17P used in NICHD trial. Am J Obstet Gynecol. 2012;207(5):e11.
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. Society for Maternal-Fetal Medicine. Information update on 17a-hydroxyprogesterone caproate (17P) from the American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine. October 13, 2011.
   Google Scholar
• United States Food and Drug Administration. Questions and answers on updated FDA statement on compounded versions of hydroxyprogesterone caproate (the active ingredient in Makena). June 2012; [cited 2020 Mar 29]. Available from: https://wayback.archive-it.org/7993/20170113105722/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm310215.htm.
   Google Scholar
• United States Food and Drug Administration. FDA’s human drug compounding progress report: Three years after enactment of the Drug Quality and Security Act. January 2017; [cited 2020 Mar 27]. Available from: https://www.fda.gov/drugs/human-drug-compounding/fdas-human-drug-compounding-progress-report-three-years-after-enactment-drug-quality-and-security.
   Google Scholar
• Raymond N. US prosecutors seek 35 years in prison for meningitis outbreak exec. June 23, 2017; [cited 2020 Mar 27]. Available from: https://www.reuters.com/article/us-massachusetts-meningitis-idUSKBN19E1GR.
   Google Scholar
• MAKENA® (hydroxyprogesterone caproate injection) for intramuscular use [package insert]. Waltham (MA): Amag Pharmaceuticals, Inc; 2018.
   Google Scholar
• Krop J, Kramer WG. Comparative bioavailability of hydroxyprogesterone caproate administered via intramuscular injection or subcutaneous autoinjector in healthy postmenopausal women: a randomized, parallel group, open-label study. Clin Ther. 2017;39(12):2345–2354.
   PubMed Web of Science ®Google Scholar
• Stone RH, Bobowski C, Milikhiker N, et al. Prevention of preterm labor with 17α-hydroxyprogesterone (17OHP) caproate: a comparison of adverse drug reaction rates between compounded and commercial formulations. Am J Perinatol. 2017;34(14):1436–1441.
   PubMed Web of Science ®Google Scholar
• Blackwell SC, Gyamfi-Bannerman C, Biggio JR, Jr, et al. 17-OHPC to prevent recurrent preterm birth in singleton gestations (PROLONG Study): a multicenter, international, randomized double-blind trial. Am J Perinatol. 2020;37(02):127–136.
   PubMed Web of Science ®Google Scholar
• Amag Pharmaceuticals, Inc. Amag Pharmaceuticals announces topline results from the PROLONG trial evaluating MAKENA® (hydroxyprogesterone caproate injection). March 8, 2019; [cited 2020 May 20]. Available from: https://www.amagpharma.com/news/amag-pharmaceuticals-announces-topline-results-from-the-prolong-trial-evaluating-makena-hydroxyprogesterone-caproate-injection/.
   Google Scholar
• Eke AC, Sheffield J, Graham EM. 17a-hydroxyprogesterone caproate and the risk of glucose intolerance in pregnancy. A systematic review and meta-analysis. Obstet Gynecol. 2019;133(3):468–475.
   PubMed Web of Science ®Google Scholar
• Division of Bone, Reproductive, and Urologic Products. Office of New Drugs, Center for Drug Evaluation and Research. Food and Drug Administration. Bone, Reproductive, and Urologic Drugs Advisory Committee (BRUDAC). Transcript for the October 29, 2019 Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC). October 2019; [cited 2020 May 21]. Available from: https://www.fda.gov/media/136108/download.
   Google Scholar
• O'Brien JM, Adair CD, Lewis DF, et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2007;30(5):687–696.
   PubMed Web of Science ®Google Scholar
• Norman JE, Marlow N, Messow C-M, et al. Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial. Lancet. 2016;387(10033):2106–2116.
   PubMed Web of Science ®Google Scholar
• Crowther CA, Ashwood P, McPhee AJ, et al. Vaginal progesterone pessaries for pregnant women with a previous preterm birth to prevent neonatal respiratory distress syndrome (the PROGRESS study): a multicentre, randomised, placebo-controlled trial. PLoS Med. 2017;14(9):e1002390.
   PubMed Web of Science ®Google Scholar
• United States Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Centers for Biologics Evaluation and Research (CBER). Center for Veterinary Medicine (CVM). Office of Regulatory Affairs (ORA). Guidance for industry. Quality systems approach to pharmaceutical current good manufacturing practice regulations. September 2006; [cited 2020 Mar 27]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/quality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations.
   Google Scholar
• United States Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Office of Compliance/OUDLC. Guidance for industry. Compounding drug products that are essentially copies of approved drugs under section 503B of the Federal, Food, Drug, and Cosmetic Act. January 2018; [cited 2020 Apr 14]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compounded-drug-products-are-essentially-copies-approved-drug-products-under-section-503b-federal.
   Google Scholar
• The Pew Charitable Trusts. U.S. Illnesses and deaths associated with compounded or repackaged medications, 2001-19. March 2020; [cited 2020 Apr 14]. Available from: https://www.pewtrusts.org/en/research-and-analysis/data-visualizations/2020/us-illnesses-and-deaths-associated-with-compounded-or-repackaged-medications-2001-19.
   Google Scholar
• United States Food and Drug Administration. Limited FDA Survey of Compounded Drug Products. 2001; [cited 2020 Mar 29]. Available from: https://www.fda.gov/drugs/human-drug-compounding/report-limited-fda-survey-compounded-drug-products.
   Google Scholar
• United States Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Centers for Biologics Evaluation and Research (CBER). Guidance for industry. Drug master files (draft guidance). October 2019; [cited 2020 Mar 29]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-master-files-guidance-industry.
   Google Scholar
• Simon JA. The Woman’s Health Initiative and one of many unintended consequences. Menopause. 2016;23(10):1057–1059.
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. Committee on Gynecologic Practice and the American Society for Reproductive Medicine Practice Committee. Compounded bioidentical menopausal hormone therapy. Committee opinion number 532. August 2012; [cited 2020 Mar 29]. Available from: https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2012/08/compounded-bioidentical-menopausal-hormone-therapy.
   Google Scholar
• North American Menopause Society. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728–753.
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. ACOG statement on 17P hydroxyprogestrone caproate. October 2019; [cited 2020 Mar 29]. Available from: https://www.acog.org/news/news-releases/2019/10/acog-statement-on-17p-hydroxyprogesterone-caproate.
   Google Scholar
• Society for Maternal-Fetal Medicine Publications Committee. SMFM Statement: Use of 17-alpha hydroxyprogesterone caproate for prevention of recurrent preterm birth. October 2019; [cited 2020 Mar 29]. Available from: https://els-jbs-prod-cdn.literatumonline.com/pb/assets/raw/Health%20Advance/journals/ymob/SMFM_Statement_PROLONG-1572023839767.pdf.
   Google Scholar